Your browser doesn't support javascript.
loading
Noninvasive tests maintain high accuracy for advanced fibrosis in chronic hepatitis B patients with different nomenclatures of steatotic liver disease.
Chen, Lin; Tao, Xuemei; Zeng, Minghui; Li, Yuqin; Han, Jiaxin; Wang, Yuekui; Liu, Yonggang; Shi, Ruifang; Su, Rui; Xu, Liang; Mi, Yuqiang.
Afiliación
  • Chen L; Clinical School of the Second People's Hospital, Tianjin Medical University, Tianjin, China.
  • Tao X; Department of Hepatology, Tianjin Second People's Hospital, Tianjin, China.
  • Zeng M; Medical School of Chinese People's Liberation Army (PLA), Beijing, China.
  • Li Y; Department of Pathology and Hepatology, the Fifth Medical Center of PLA General Hospital, Beijing, China.
  • Han J; Clinical School of the Second People's Hospital, Tianjin Medical University, Tianjin, China.
  • Wang Y; Department of Hepatology, Tianjin Second People's Hospital, Tianjin, China.
  • Liu Y; Clinical School of the Second People's Hospital, Tianjin Medical University, Tianjin, China.
  • Shi R; Department of Hepatology, Tianjin Second People's Hospital, Tianjin, China.
  • Su R; Clinical School of the Second People's Hospital, Tianjin Medical University, Tianjin, China.
  • Xu L; Department of Hepatology, Tianjin Second People's Hospital, Tianjin, China.
  • Mi Y; Clinical School of the Second People's Hospital, Tianjin Medical University, Tianjin, China.
J Med Virol ; 96(4): e29613, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38634477
ABSTRACT
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a new nomenclature proposed in 2023. We aimed to compare the diagnostic efficacy of noninvasive tests (NITs) for advanced fibrosis under different nomenclatures in patients with chronic hepatitis B (CHB). A total of 844 patients diagnosed with CHB and concurrent steatotic liver disease (SLD) by liver biopsy were retrospectively enrolled and divided into four groups. The performances of fibrosis-4 (FIB-4), gamma-glutamyl transpeptidase to platelet ratio index (GPRI), aspartate aminotransferase to platelet ratio index (APRI), and liver stiffness measurement (LSM) were compared among the four groups. The four NITs showed similar diagnostic efficacy for nonalcoholic fatty liver disease (NAFLD), MASLD, and metabolic dysfunction-associated fatty liver disease (MAFLD) in patients with CHB with advanced fibrosis. LSM showed the most stable accuracy for NAFLD (AUC = 0.842), MASLD (AUC = 0.846), and MAFLD (AUC = 0.863) compared with other NITs (p < 0.05). Among the four NITs, APRI (AUC = 0.841) and GPRI (AUC = 0.844) performed best in patients with CHB & MetALD (p < 0.05). The cutoff value for GPRI in patients with CHB & MetALD was higher than that in the other three groups, while further comparisons of NITs at different fibrosis stages showed that the median GPRI of CHB & MetALD (1.113) at F3-4 was higher than that in the CHB & MASLD group (0.508) (p < 0.05). Current NITs perform adequately in patients with CHB and SLD; however, alterations in cutoff values for CHB & MetALD need to be noted.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hepatitis B Crónica / Enfermedad del Hígado Graso no Alcohólico Límite: Humans Idioma: En Revista: J Med Virol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hepatitis B Crónica / Enfermedad del Hígado Graso no Alcohólico Límite: Humans Idioma: En Revista: J Med Virol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos